Company also engaged in business partnerships with global biopharmaceutical companies
[by Yu, Suin] ENCell announced on June 16 that it participated in the International Society for Stem Cell Research (ISSCR) 2025 Annual Conference, held in Hong Kong from June 11 to 14 (local time), where it presented the results of the Phase 1 clinical trial for its investigational new drug, 'EN001 (development code).'
The ISSCR Annual Meeting is one of the world’s largest academic conferences dedicated to stem cell research, attracting approximately 4,000 participants from over 70 countries each year. 바카라 에볼루션 took part in the event for the first time and presented the Phase 1 clinical trial results of its investigational new drug candidate, EN001, at 5 p.m. on June 13.
바카라 에볼루션 reported receiving a highly positive local response following its presentation of long-term follow-up data from the Phase 1 single-dose clinical trial of EN001, targeting patients with 'Charcot-Marie-Tooth Disease 1A (CMT1A).’ The company highlighted that no adverse events were observed for up to 48 weeks, thereby demonstrating EN001’s safety profile. Furthermore, results from the exploratory efficacy assessment indicated that therapeutic effects were maintained even in the high-dose group.
Beginning this year, ISSCR implemented a one-on-one partnering system, and 바카라 에볼루션 used this opportunity to engage in partnership discussions with leading global biotechnology companies in the stem cell treatment sector. In addition to actively promoting its pipeline, including EN001, which was recently granted ‘orphan drug designation’ from the U.S. Food and Drug Administration (FDA), the company also pursued opportunities for global contract development and manufacturing (CDMO) orders and licensing-out agreements.
“This conference confirmed the strong local interest in the clinical results of EN001. As we continue with additional clinical trials, we anticipate increased potential for licensing-out opportunities,” an 바카라 에볼루션 official said. “We intend to actively promote the company at major Korean and international conferences to highlight our globally competitive technology and future growth potential.”